The Consortium continues to increase its membership of growing companies in the field of Alzheimer’s disease. As of June 2016, there are over 50 people registered on the mailing list. Please continue to introduce new members and/or companies that may be interested and make suggestions for ideas and events for the AABC to better serve its membership. Going forward we will aim to send out newsletters every quarter. We have added two new sections to the newsletter: “News from AABC members and growth AD companies” and “AABC collaboration”. For future issues please let us know if there is content that you would like to us to include.

For those of you not familiar with the AABC, we encourage you to get involved in 2016 by attending one of our events. Please email Charles Stacey (cstacey@accerapharma.com), Kira Sheinerman (ksheinerman@diamirbio.com) or Jim Hendrix (jhendrix@alz.org) to be added to the membership list mailing list.

Mission of the AABC

The mission of the AABC is to advance Alzheimer’s disease research and innovation in small/medium-sized biotechnology, diagnostics, medical device, and contract research organizations.

The AABC works to achieve their mission by working in areas of common interest in a pre-competitive space to advance both the field of Alzheimer’s research and the member company’s goals. The AABC member companies provide leadership and direction to the organizations areas of focus that include but are not limited to: Collaborations, Recognition & Visibility and Knowledge and Information Sharing.

News from AABC members and growth AD companies

May 31, 2016: Swiss biotech firm AC Immune SA filed with U.S. regulators to raise up to $50 million in an initial public offering of common stock. AC Immune, backed by German billionaire Dietmar Hopp, said it plans to use proceeds from the IPO to develop products, including the Alzheimer’s drug crenezumab.

May 12, 2016: Accera, Inc. announced that it has completed enrollment of the NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of mild to moderate Alzheimer’s disease. The company expects to report top-line data in December.
May 9, 2016: AC Immune announced that it raised approximately USD 43.5 million (CHF 42.7 million) in a private financing.

May 5, 2016: ProMIS Neurosciences today announced that, following the previously announced identification of its first three targets, it has identified a fourth in a series of novel potential therapeutic targets on strains of misfolded Amyloid beta (Aβ), implicated in the development and progression of Alzheimer’s disease (AD).

April 6, 2016: Allergan and Heptares Therapeutics announced they have entered into a definitive agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.

April 1, 2016: Tetra Discovery Partners ("Tetra") today announced that the company has successfully completed its initial Phase 1 single ascending dose (SAD) study of BPN14770 safety in 32 healthy volunteers. BPN14770 is the company's experimental treatment aimed at improving memory and slowing the progression of Alzheimer's disease. Tetra plans to begin its second Phase 1 trial of BPN14770 in June, which will study multiple ascending doses (MAD).

February 17, 2016: M3 Biotechnology, Inc. - Dolby Family Ventures, a venture fund managing a portfolio of investments specifically focused on companies targeting Alzheimer’s and similar neurodegenerative disease, is backing Seattle-based M3 Biotechnology, Inc., according to M3 CEO Leen Kawas, Ph.D.

January 22, 2016: Brain Reader - The January edition of Radiology Today features an article about Brainreader’s Neuroreader™software. In the article, John L. Ulmer, MD, chief of neuroradiology at the Medical College of Wisconsin, praises Neuroreader™ by saying that the software bridges some important gaps that have prevented neurology from moving in this direction sooner (i.e. increasing the quantification of medical practice).

January 11, 2016: DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests, announced today that it has entered into a research collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Johnson & Johnson Innovation facilitated the agreement.

January 6, 2016: Cortexyme Inc. raised $15 million in Series A financing led by Pfizer Inc. along with new investment from Takeda Pharmaceutical Company Ltd., through its venture arm, and other private investors. Existing investors such as Dolby Family Ventures also participated.

Schedule of Events for Q3 and Q4 2016

1. **Webinar: Fundraising for Alzheimer’s Disease companies**

   **Date:** June 29th 2016, 8:00–8:55 am PT/ 11:00-11:55 ET
   **Topics:** Is the investor environment getting better or worse? Top tips for companies looking to fund raise this year Lessons in investor selection
Most common areas of focus in investor due diligence

Panelists: To include companies that have recently raised funds and investors that have recently invested in AD
Moderator: Charles Stacey – Co-Chair of the AABC and CEO, Accera, Inc.

2. AABC Networking Event at the Alzheimer’s Association International Conference (AAIC)
Monday, July 25th 2016, 7-9 pm
Parkdale Room, Delta Hotel, 75 Lower Simcoe Street, Toronto

The aim of this event is to give you, the AABC members, the chance to meet and network with your fellow AABC members. In addition, we recognize one goal of the AABC is to expand our reach and network. We encourage you to extend this invitation to other like-minded scientists and entrepreneurs who may be in attendance at AAIC. They don’t need to be members of the AABC to attend.

Drinks and light hors d’oeuvres will be served. RSVP to: mmcneil@alz.org

3. Webinar: Raising non-dilutive capital in Alzheimer’s Disease
Date: TBC in September 2016

4. Webinar: Success stories in Alzheimer’s Disease
Date: TBC in November 2016
Topics: Specific successes that AD companies have experienced
Panelists: TBC
Moderator: Kira Sheinerman – Co-Chair of the AABC and CEO, DiamiR Biosciences

5. AABC Networking Event during CTAD 2016, San Diego, USA
Date: Date/time and venue TBC

AABC Collaboration

Job postings

Accera, a clinical stage biotechnology company with the lead compound (AC-1204) in Phase 3 for mild-moderate Alzheimer’s disease, are looking to recruit a: VP and Director of CMC and a Srn. Director/Director of project management. If you are interested, or know of potential candidates, please contact Charles Stacey on: cstacey@accerapharma.com or hr@accerapharma.com for a full job description.

To post your job listings in future newsletters, please inform Charles Stacey on: cstacey@accerapharma.com
General postings to the AABC membership

To post any general postings in future newsletters, please inform Charles Stacey on:

cstacey@accerapharma.com

Past Events

1. Alzheimer’s Disease Investment Panel @ BioTech Showcase 2016
   Topic: Alzheimer’s disease: has the tide turned?
   Date: Monday, January 11th 2016, 8:00–8:55 am
   Confirmed Panelists: Andrew Fein – Senior Biotechnology Analyst, HC Wainwright; Jim Hendrix – Director, Global Science Initiatives, Alzheimer’s Association; Guy Seabrook – VP, Neuroscience Innovation, J&J Innovation. Moderator: Charles Stacey – Co-Chair of the AASCC and CEO, Accera

2. Webinar: What does pharma look for in evaluating companies as potential partners?
   Date: February 24 at 11 am ET / 8 am PT.
   Speaker: Declan Jones, Vice President, Neuroscience Lead, J & J Innovation Center

Stay tuned for other events and updates.

Best wishes,

Jim Hendrix, Charles Stacey and Kira Sheinerman